⌘+K

Latest share price

SEK

21.7

-4.63%

20 Nov 2026 17:29 CET

Fair value range

SEK

35.0

—

55.0

30 Oct 2026

Market cap

SEK

639

m

EQL Pharma

Healthcare

2026-11-06

Entering the next phase of recovery - Q2 review

Q2 was significantly above expectations, although temporary factors contributed materially to the beat. The operational recovery is encouraging, with management more...

Post-Results Note

Erik Hultgård

Arvid Necander

Entering the next phase of recovery - Q2 review

Q2 2026/27 initial - significantly ahead on sales and margins

Restocking and easier comparables - Q2 preview

EQL Pharma

Healthcare

2026-11-05

Q2 2026/27 initial - significantly ahead on sales and margins

Q2 beat our expectations significantly, partly driven by temporary sales contributions. Improving availability and strong adjusted margins are encouraging, although the...

News

Erik Hultgård

Arvid Necander

Entering the next phase of recovery - Q2 review

Q2 2026/27 initial - significantly ahead on sales and margins

Restocking and easier comparables - Q2 preview

EQL Pharma

Healthcare

2026-10-30

Restocking and easier comparables - Q2 preview

We expect a more favourable comparison and progress on restocking to support a return to sales growth in Q2 2026/27. We forecast a sequential improvement in the adj....

Pre-Results Note

Erik Hultgård

Arvid Necander

Entering the next phase of recovery - Q2 review

Q2 2026/27 initial - significantly ahead on sales and margins

Restocking and easier comparables - Q2 preview

Price chart

Price

Fair range high value

Fair range low value

Year

2024

2025

2026e

2027e

2028e

EPS

1.48

0.42

0.30

2.18

3.65

EPS (Adj.)

1.56

0.86

1.48

2.18

3.65

Sales Growth

41.39%

15.83%

17.51%

21.78%

21.98%

EPS Growth (Adj.)

53.27%

-44.42%

71.52%

47.20%

67.40%

P/E

14.6

51.0

72.6

9.9

5.9

P/E (Adj.)

13.9

25.0

14.6

9.9

5.9

EV/EBITA

14.8

20.6

25.7

9.5

6.1

EV/EBITDA

12.4

13.7

14.7

7.3

5.0

Learn more

Key facts

Sector

Healthcare

Country

Sweden

Tickers

EQL@SS, EQL.ST

CEO

Axel Schörling

CFO

Anna Jönsson

About DNB Carnegie Access

DNB Carnegie Access aim is to connect listed companies with the capital markets. Through top ranked public equity research and broad distribution via written reports, seminars, video, and podcasts, we increase visibility and investor understanding for small- and medium-sized companies, both among institutional and private investors.

Along with corporate finance, market making and certified advisory we provide a complete product offering to our clients.

Private Banking

Tailored wealth management. Your financial future, personalized.

Montrose

A digital investment platform designed for passionate investors.

DNB Carnegie

Leading Nordic investment bank and wealth management.

© Copyright DNB Carnegie Investment Bank AB